Razoxana [Inn-Spanish]

Razoxana [Inn-Spanish] Brand names, Razoxana [Inn-Spanish] Analogs

Razoxana [Inn-Spanish] Brand Names Mixture

No information avaliable

Razoxana [Inn-Spanish] Chemical_Formula

C₁₁H₁₆N₄O₄

Razoxana [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic2/dexrazoxane.htm

Razoxana [Inn-Spanish] fda sheet

Razoxana_[Inn-Spanish] FDA

Razoxana [Inn-Spanish] msds (material safety sheet)

Razoxana_[Inn-Spanish] MSDS

Razoxana [Inn-Spanish] Synthesis Reference

No information avaliable

Razoxana [Inn-Spanish] Molecular Weight

268.269 g/mol

Razoxana [Inn-Spanish] Melting Point

191 - 197 ^oC

Razoxana [Inn-Spanish] H₂O Solubility

Sparingly soluble

Razoxana [Inn-Spanish] State

Solid

Razoxana [Inn-Spanish] LogP

-2.135

Razoxana [Inn-Spanish] Dosage Forms

Liquid; Powder for solution

Razoxana [Inn-Spanish] Indication

For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.

Razoxana [Inn-Spanish] Pharmacology

Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose.

Razoxana [Inn-Spanish] Absorption

IV administration results in complete bioavailability.

Razoxana [Inn-Spanish] side effects and Toxicity

Intraperitoneal, mouse LD₁₀ = 500 mg/kg. Intravenous, dog LD₁₀ = 2 gm/kg.

Razoxana [Inn-Spanish] Patient Information